How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer
Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video LibraryDrs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.
Related Videos
Ibrutinib and ABT199 for CLL
Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.
Targeted Therapies and their Impact on Melanoma
Dr. Steve O’Day works with melanoma and has seen great breakthroughs in targeted therapies and their impact on the disease.